NEUROCRINE BIOSCIENCES INC (NBIX) Stock Profile — Insider Trades & Financials

Revenue$805.5M

Net Income$153.7M

EPS$4.67

Market Cap$13.1B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Kyle W. Gano

CEO & Executive Director

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

Employees: 1,350
Headquarters: SAN DIEGO, CA, United States
Website: www.neurocrine.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

4.72%

ROA?

3.32%

D/E Ratio?

0.42

Op. Margin?

26.18%

📊

Profitability Ratios

Net Margin?

19.08%

Loading company sections...

NEUROCRINE BIOSCIENCES INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness